RESTON, Va., Oct. 8, 2026 /PRNewswire/ — V2X, Inc., (NYSE: VVX), a leading provider of global mission solutions, will report third quarter 2026 financial results on Monday, November 2, 2026, after market close. Senior management will conduct a conference call at 4:30 p.m. ET that same day.
U.S.-based participants may dial in to the conference call at 833-862-0305, while international participants may dial 412-634-6017. A live webcast of the conference call as well as an accompanying slide presentation will be available at https://app.webinar.net/rqDM9X62Bez and on the Investors section of the V2X website at https://gov2x.com/.
A replay of the conference call will be posted on the V2X website shortly after completion of the call and will be available for one year. A telephonic replay will also be available through November 16, 2026, at 844-512-2921 (domestic) or 412-317-6671 (international) with passcode 10212511.
About V2X V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.
Investor Contact Mike Smith, CFA Vice President, Treasury, Corporate Development and Investor Relations [email protected] 719-637-5773
The average 30-year fixed mortgage rate reached 7.4% this week, according to Freddie Mac survey data through Wednesday, up from 7.28% a week earlier and the highest level in nearly three years. Other measures are higher still. Mortgage News Daily calculated 7.59% as of Wednesday, the Mortgage Bankers Association reported a 7.49% average for the week through Friday, and Zillow data showed a 7.52% rate on a 30-year purchase loan today.
The climb has been steady. Freddie Mac’s 30-year average was 6.65% in late August, which means borrowing costs have risen by roughly three-quarters of a percentage point in about seven weeks. The average crossed 7% in late September for the first time in nearly three years and has kept climbing. On a $400,000 loan, a 7.4% rate means principal and interest of roughly $2,770 a month, about $290 more than at the 6.3% level of a year ago.
Mortgage rates are following bond yields higher as investors worry about government spending, inflation tied to the Iran war, and ongoing economic growth. The 10-year Treasury yield has hovered around 5.3% this week, retreating slightly after briefly touching its highest level since 2002. That link to long-term yields explains why mortgage rates have kept rising even as expectations for another Fed hike in October have faded, since home loan costs track the bond market more closely than the Fed’s policy rate.
The housing market is showing the strain. One housing economist said the higher rates have unsettled the market, noting that pending home sales fell from a year earlier in both August and September, before rates even crossed 7%, and that sellers are cutting prices at a pace not seen in four years. Higher rates reduce what buyers can afford, which pushes sellers to lower prices to attract them, and it keeps many existing homeowners with lower-rate loans from listing at all.
Refinancing is not offering much of an escape either. Zillow data put the average 30-year refinance rate at 7.41% today and the 15-year at 6.76%, while 15-year purchase loans averaged 6.70%. For buyers weighing alternatives, a 5/1 adjustable-rate mortgage averaged 7.13%, only modestly below the 30-year fixed, which limits the appeal of taking on adjustable-rate risk.
Several upcoming data points will show whether rates are close to a peak: next week’s Freddie Mac survey, the September inflation report, and the Fed’s October 27 and 28 meeting, where futures see only a small chance of another hike.
For small and microcap investors, the mortgage market is a useful read on how long-term rates are feeding into the real economy. Housing-linked businesses, from builders and building products suppliers to real estate services and home improvement retailers, are typically among the first to feel higher borrowing costs, and smaller companies with less pricing power and more floating-rate debt feel it more acutely. Mortgage-related financial companies face the same pressure through lower loan volumes. Because long yields, not the Fed, are driving this move, relief is likely to depend on easing concerns about deficits and inflation rather than on the central bank pausing.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
MAIA Reported Two Important Clinical Trial Milestones. MAIA announced the completion of enrollment for the Part C Expansion Stage of the THIO-101 trial. This part of THIO-101 has enrolled 150 patients. Separately, the Phase 3 THIO-104 trial reached enrollment of 65 patients, putting it on schedule to enroll 100 patients by YE2026. Reaching the full-year enrollment goal could allow an interim analysis in FY2027.
Results From THIO-101 Part C Have Been Positive To Date. As discussed in our Research Note on September 22, MAIA recently announced initial efficacy data from the THIO-101 Part C. The evaluable population, consisting of patients with at least one post-treatment evaluation by tumor scan, showed a disease control rate (DCR) of 90.5%. This far exceeds published studies that show a 25%–35% DCR for standard third-line chemotherapy regimens.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Minutes from the Federal Reserve’s September 16 meeting, released Wednesday, show that every participant agreed interest rates needed to move higher. The committee voted unanimously to raise the federal funds rate, its first increase in three years, and most members projected at least one more quarter-point hike before the end of the year.
The minutes describe a committee that saw inflation as elevated and the labor market as near full employment, with some signs of strengthening. Economic activity was expanding at a solid pace. Almost all participants judged that risks to inflation were tilted to the upside, while risks to the labor market had diminished and were now broadly balanced. That balance of risks was the basis for the hike.
But the data since that meeting has shifted the picture. Core PCE inflation, the Fed’s preferred gauge, rose 3% in August, below the 3.3% economists expected and down from 3.3% in July. Then the September jobs report came in far weaker than forecast, with just 29,000 jobs added and the unemployment rate edging up to 4.2% from 4.1%. In other words, the two conditions that justified the hike, stubborn inflation and a firming labor market, both looked softer within weeks.
Several officials had already begun tempering expectations before the jobs report. Vice Chair Philip Jefferson and New York Fed President John Williams both acknowledged that inflation remains too high but said the central bank should take time to assess whether it is on a downward path. Williams said there is no need for urgency after the September increase and that the Fed has time to gather more information. That marks a notable shift from late September, when other officials were publicly arguing that more hikes were needed. Core inflation at 3% is still well above the Fed’s 2% target, so the debate now appears to be about timing rather than direction.
Markets have adjusted accordingly. The Fed meets again October 27 and 28, and futures now price only about a 17% chance of a hike at that meeting, down from roughly two-thirds in late September. The odds of a hike in December sit near 70%, which suggests traders see the Fed pausing rather than finishing.
A pause would not necessarily bring relief to long-term borrowing costs. The 10-year Treasury yield is still near 5.3%, and much of the recent rise has reflected investors demanding higher real returns to hold long-dated debt rather than the Fed’s policy rate, a dynamic that a pause in hikes may do little to change.
For small and microcap investors, the shift matters. Roughly 32% of Russell 2000 companies carry floating-rate debt, compared with about 6% of S&P 500 companies, so changes in the expected path of short-term rates flow more directly into smaller companies’ interest costs. A pause at the current range of 3.75% to 4.00% would stabilize that expense, while a December hike would extend it. The weaker jobs data cuts both ways, since easing rate pressure helps leveraged balance sheets but a cooling labor market can hurt consumer-facing companies that depend on household spending, such as restaurant operator The ONE Group Hospitality and travel deals publisher Travelzoo.
Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study
CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone with 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor (CPI) in the ongoing Phase 2 and pivotal Phase 3 clinical trials of its novel telomere-targeting agent ateganosine as a treatment for non-small cell lung cancer (NSCLC).
Enrollment is complete for the Part C of Phase 2 trial, THIO-101, which evaluates ateganosine sequenced with the CPI cemiplimab. MAIA recently announced 90.5% interim disease control (DCR) for the combination therapy in the efficacy evaluable population who had at least one tumor scan after starting treatment. Ateganosine’s measures of efficacy are close to triple the reported outcome for standard-of-care treatment with chemotherapy.
THIO-104 is MAIA’s pivotal Phase 3 trial evaluating ateganosine in sequence with a CPI in third line (3L) NSCLC patients whose disease has progressed following chemotherapy and CPI treatment. MAIA announced the first patient dosed in December 2025, and enrollment and dosing continues to advance at a strong pace. To date, 65 patients have been enrolled. The trial is targeting 100 patients enrolled and dosed by year-end.
“Our Phase 2 THIO-101 trial is on track to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment,” said Vlad Vitoc, M.D., Founder and CEO of MAIA. “Our strategic focus on third-line NSCLC addresses a critical treatment gap for patients who have progressed after immunotherapy and chemotherapy, with no established standard of care today. Clinical data to date supports ateganosine’s potential to define a new treatment category for this difficult-to-treat population.
“For THIO-104, we have reached 65% of our enrollment target of 100 patients by year-end 2026, and remain on track with our target to conduct an interim analysis in 2027,” Dr. Vitoc added.
The U.S. Food and Drug Administration (FDA) granted Fast Track designation for ateganosine for the treatment of NSCLC in July 2025. The designation allows for more frequent FDA communication, potential rolling review, and eligibility for Accelerated Approval and Priority Review. If approved, ateganosine will hold FDA New Chemical Entity (NCE) five-year marketing exclusivity. An NCE is a small molecule drug with a novel active ingredient that has not been previously approved or marketed.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About THIO-101 Phase 2 Clinical Trial
THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.
About THIO-104 Phase 3 Clinical Trial
THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. For more information on this Phase 3 trial, please visit ClinicalTrials.gov using the identifier NCT06908304.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005
Cadrenal has received strong interest from potential strategic partners
Cadrenal will explore all strategic alternatives including corporate partnerships and other strategic transactions
PONTE VEDRA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio.
The initiative builds on Cadrenal’s ongoing strategic partnering discussions and will evaluate a broad range of potential transactions involving the Company and its clinical- and development-stage programs, including CAD-1005, tecarfarin, frunexian, and CAD-2000, the Company’s second-generation 12-LOX platform. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions.
Cadrenal has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor in connection with the process.
“Our pipeline has reached critical clinical and regulatory maturity, anchored by our recent alignment with the FDA on the Phase 3 development pathway for CAD-1005,” said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. “Having received strong interest from potential strategic partners, we believe a formal strategic process provides the appropriate framework to evaluate opportunities across our portfolio and determine the paths that can maximize value for our shareholders while advancing these programs for patients.”
There can be no assurance that the strategic process will result in any transaction or other strategic outcome. Cadrenal does not intend to provide updates on the process unless and until its Board of Directors approves a specific transaction or course of action, or the Company otherwise determines that disclosure is appropriate or required.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company’s portfolio comprises clinical- and development-stage programs addressing significant unmet needs in critical care cardiology and orphan cardiovascular conditions.
CAD-1005 is a first-in-class 12-lipoxygenase (12-LOX) inhibitor in development to treat heparin-induced thrombocytopenia (HIT), a serious immune-mediated thrombotic disorder. CAD-1005 is designed to selectively inhibit 12-LOX, a pathway involved in platelet immune activation and thrombo-inflammatory signaling in HIT. The program has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and orphan drug status from the European Medicines Agency. Cadrenal has received FDA feedback on the pathway for a Phase 3 registration study of CAD-1005 in HIT.
Tecarfarin is a Phase 3-ready oral vitamin K antagonist under development for patients requiring chronic anticoagulation, including those with end-stage kidney disease, atrial fibrillation, and implanted left ventricular assist devices. Tecarfarin has received FDA Orphan Drug and Fast Track designations for certain indications.
Frunexian is an investigational parenteral small-molecule Factor XIa inhibitor under development for acute and critical care settings, including major cardiac surgery.
CAD-2000 is a preclinical, next-generation, orally bioavailable 12-lipoxygenase (12-LOX) inhibitor under development as an outpatient Immunology & Inflammation (I&I) platform. CAD-2000 targets adipo-inflammatory signaling and systemic lipid-driven inflammation to address chronic metabolic and cardiorenal disorders. Positioned as an oral follow-on companion to CAD-1005, the asset is optimized for broad, large-market chronic inflammatory indications, including obesity-driven systemic inflammation, metabolic-associated steatohepatitis (MASH), and chronic cardiorenal diseases. It offers potential therapeutic synergy when combined with existing blockbuster metabolic regimens. For more information, please visit www.cadrenal.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements include, among other things, statements regarding the Company’s strategic process; the potential timing, structure, benefits and outcome of that process; the possibility of any licensing transaction, asset sale, partnership, business combination or other strategic transaction; the clinical development, regulatory approval and commercialization of CAD-1005, tecarfarin, frunexian, CAD-2000 and the Company’s other programs; and the potential benefits and market opportunities associated with the Company’s product candidates.
Forward-looking statements may be identified by words such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
These risks and uncertainties include, without limitation, the possibility that the strategic process may not result in a transaction; the Company’s ability to identify, negotiate and complete any strategic transaction on acceptable terms or at all; potential disruption to the Company’s business during the strategic process; the Company’s need for additional capital and ability to obtain financing on acceptable terms; risks associated with clinical development and regulatory approval; the Company’s ability to develop and commercialize its product candidates; the Company’s ability to maintain the listing of its common stock on The Nasdaq Capital Market; and the other risks described under the heading “Risk Factors” in Cadrenal’s filings with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date of this press release, and Cadrenal undertakes no obligation to update them except as required by applicable law.
For more information, please contact:
Cadrenal Therapeutics, Inc. Quang X. Pham, CEO (904) 300-0701 [email protected]
Stocks are at records, credit markets are showing strain, and small caps are in the middle of the debate. The picture is more mixed than the headlines suggest.
The S&P 500 and Nasdaq hit record highs on Tuesday. The Russell 2000 closed at 2,830, about 8% below its third-quarter high of 3,068 but still up roughly 14% this year, after finishing 2025 near 2,482. As of July, it had also outpaced the S&P 500 over six months (16.9% versus 8.9%) and one year (20.0% versus 9.9%), according to Benzinga.
The pressure is real. The 10-year Treasury yield closed at 5.27% on Tuesday, a level not seen since 2002. JPMorgan strategists say deeply distressed leveraged loans are at their highest since March 2020, and spreads on CCC-rated bonds have passed 1,000 basis points.
Those figures describe leveraged loans and junk bonds, though, not the companies in the Russell 2000.
Where small caps stand
Small caps do carry more rate risk. Interest expense takes up 31% of EBITDA at Russell 2000 companies, versus 6.7% for the S&P 500, and about 30% of their debt is floating-rate, according to July data from The Kobeissi Letter.
But that sensitivity works in both directions. When oil prices fell and rate expectations eased this spring, the Russell 2000 gained about 11.7% in the first 20 days of April, per 24/7 Wall St. The index has since recovered about 16% from its low during the Iran war selloff, breaking out of a multi-year base near 2,000 and closing the second quarter at 3,024.
Debt is concentrated, and many companies are cushioned
Not every small cap is carrying a heavy load. A 2024 Wellington analysis found that half of the Russell 2000’s debt sits with just 10% of its companies, while 33% held net cash, versus 13% for the S&P 500.
That study predates this year’s rate moves, but it points to a market where stress is concentrated rather than universal. JPMorgan’s latest data fits that pattern: technology accounts for 39% of distressed loans, with software borrowers facing more than $100 billion of maturing debt. Nearly 40% of the index’s companies are unprofitable, which also means a majority are not.
Signs of resilience
JPMorgan CEO Jamie Dimon said weeks ago, after the Federal Reserve’s September rate hike, that the labor market’s relative strength suggested higher borrowing costs had not yet turned into broader economic stress. On Tuesday, he warned that spreads could eventually widen as governments and AI spending compete for capital.
Markets are calm for now. The VIX, Wall Street’s fear gauge, closed near 15. JPMorgan projects a 2.25% default rate this year, though it expects defaults to rise next year.
What could help
Investors will be watching the 10-year yield, CCC spreads and the Fed’s next meeting under Chair Kevin Warsh. Falling yields would ease refinancing for the many small caps with debt coming due, and third-quarter earnings should show how companies are managing interest costs. Oil, trading near $90 a barrel, is another swing factor: its drop in April helped reset rate expectations.
Credit conditions are tightening, but small caps have already shown they can rebound when pressure eases. For companies with solid balance sheets, the data point to a hurdle rather than a roadblock.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
George Proost, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Q1 expectations reset. We are lowering our fiscal Q1 revenue and adj. EBITDA forecasts to $299.0 million and $72.5 million, down from $307.0 million and $77.0 million, respectively. The revision largely reflects softer-than-expected water-park results due to unfavorable weather, pricing, and season-pass decisions, as well as lingering disruption from the World Cup.
Water-park weakness appears fixable. While weather and an aggressive, roughly 30% price increase pressured attendance, per-capita spending improved, and labor costs declined. Management plans to recalibrate pricing, start selling season passes earlier, and further optimize admissions to position the parks for improved performance next season.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Debt Redemption. The GEO Group is redeeming all of its $650 million 8.625% Senior Secured Notes due in 2029. The redemption will be funded from net proceeds of the facility sale announced Monday. We view this as a significant positive for the Company, reducing outstanding debt, eliminating interest payments, and setting the Company up to be more aggressive in its share repurchase program.
Details. The redemption price for the 2029 Senior Secured Notes will be equal to $1,043.13 per $1,000.00 original principal amount, or approximately $678 million, plus any accrued and unpaid interest. GEO is receiving a net $705 million from the facility sale and had another $55 million of cash on the balance sheet as of June 30th. The redemption of the 2029 Senior Secured Notes will occur on October 15, 2026. GEO will save some $56 million in annual interest expense.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
George Proost, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Transit sale completed. Conduent completed the previously announced sale of its public transit and fare collection business to Modaxo on October 1. In our view, the closing represents another important step in the company’s efforts to simplify its portfolio, reduce financial leverage, and focus resources on its core Commercial and Government businesses.
$125 million earmarked for debt reduction. Conduent received $140 million in cash consideration at closing and expects to use $125 million of net proceeds to repay borrowings under its revolving credit facility. We view the debt reduction favorably and believe the improved balance sheet should enhance the company’s financial flexibility as management executes its ASCEND strategy.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
George Proost, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Revising estimates. We are lowering our second-half 2026 revenue expectations to reflect a softer advertising environment, including lower expectations for core and political advertising. We now forecast Q3 revenue of $42.7 million and adjusted EBITDA of $3.9 million, followed by Q4 revenue of $49.5 million and adjusted EBITDA of $6.5 million.
Cost reductions are providing support. Despite the challenging revenue environment, we believe Beasley’s significantly lower operating cost structure is beginning to meaningfully benefit profitability. We forecast full-year 2026 revenue to decline 13.1% to $178.9 million, while adjusted EBITDA increases 45.2% to $15.3 million and the adjusted EBITDA margin expands to 8.5% from 5.1% in 2025.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Presentation to Highlight Single-Dose MVA and Continuous Cell-Line MVA Manufacturing Innovations
ATLANTA, GA – October 06, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that Senthil Ranganathan, PhD, Vice President, Technical Development and CMC Operations, will present at World Vaccine Congress Europe 2026, being held October 19–22, 2026, at RAI Amsterdam in Amsterdam, Netherlands.
Dr. Ranganathan will deliver a presentation titled “Revolutionizing MVA – Single Dose and Continuous Cell-Line Manufacturing,” highlighting GeoVax’s progress in advancing next-generation Modified Vaccinia Ankara (MVA) technologies focused on two complementary objectives: achieving robust immunity following a single vaccine administration and establishing a scalable continuous cell-line MVA-manufacturing platform.
Presentation Details
Workshop/Track: Platform Technologies Presentation: “Revolutionizing MVA – Single Dose and Continuous Cell-Line Manufacturing” Presenter: Senthil Ranganathan, PhD, Vice President, Technical Development and CMC Operations Date: Monday, October 19, 2026 Time: 11:00 a.m. Location: RAI Amsterdam, Amsterdam, Netherlands
Advancing the MVA Platform
MVA has a decades-long history as a well-characterized vaccine platform and is increasingly important for addressing emerging infectious diseases and biodefense threats. However, broader deployment of MVA-based vaccines can be constrained by multi-dose vaccination regimens and manufacturing processes dependent on primary avian cells.
Dr. Ranganathan’s presentation will highlight GeoVax’s work to address both challenges through advances in vaccine design and manufacturing:
Single-Dose MVA Innovation: GeoVax’s next-generation MVA-X technology is being developed to enhance immune responses and potentially enable effective vaccination following a single administration. Preclinical studies with MVA-X have demonstrated protective immune responses following a single administration, supporting its potential for simplified vaccination regimens and more rapid deployment during outbreaks and public-health emergencies. Earlier this year, data presented at World Vaccine Congress Washington demonstrated that a single administration of MVA-X achieved protective efficacy comparable to a traditional two-dose MVA regimen in a murine orthopoxvirus challenge model, with protection maintained through Day 150.
Continuous Cell-Line MVA-Manufacturing: In parallel, GeoVax is advancing production of MVA using the AGE1.CR.pIX continuous avian cell line as an alternative to traditional chicken embryo fibroblast (CEF)-based manufacturing. GeoVax has demonstrated proof-of-concept of the upstream process and the downstream process is in development to support production at the 200-liter scale, with a pathway toward 500-liter and larger-scale manufacturing. This manufacturing approach is designed to enable scalable and reproducible production, reduce reliance on primary-cell supply chains, and facilitate manufacturing expansion and technology transfer. Continuous cell-line manufacturing could also provide a more flexible foundation for rapidly increasing MVA vaccine production in response to emerging infectious-disease and biodefense requirements.
Together, these advances represent a potential evolution of the MVA platform – from conventional multi-dose vaccination and primary-cell manufacturing toward single-dose immunization supported by scalable continuous cell-line production.
David A. Dodd, Chairman and Chief Executive Officer of GeoVax, commented, “MVA is an important and well-established vaccine platform, and we believe there are significant opportunities to further improve how MVA-based vaccines are administered and manufactured. Our work with MVA-X and AGE1.CR.pIX addresses both sides of that equation – potentially simplifying vaccination through a single-dose approach while establishing a scalable manufacturing platform capable of supporting broader and more responsive vaccine supply.”
Dodd continued, “Senthil’s participation in the Platform Technologies workshop at World Vaccine Congress Europe provides an important opportunity to share GeoVax’s progress with the global vaccine community. Bringing together next-generation vaccine design and scalable manufacturing has potentially important implications for outbreak response, pandemic preparedness, biodefense, strategic stockpiling, and expanded global access to MVA-based vaccines.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
New ISG research finds revenue and profit are top priorities for marketers, but returns lag expectations
STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, today announced the launch of ISG Marketing Advisory, a comprehensive suite of consulting, design and implementation services for enterprise marketing leaders.
The new practice helps marketing organizations strengthen financial accountability and translate productivity and performance into measurable return on investment. The business launches as the new ISG State of Enterprise AI: The AI Value Gap report, based on a survey of 400 executives at large global organizations – including marketing leaders – finds a significant gap between investments, productivity gains and marketing’s financial results.
“The role of the Chief Marketing Officer is entering a new era of enterprise influence,” said Kaveri Camire, partner, ISG Marketing Advisory. “Brand, customer engagement and demand generation remain essential, but AI is rapidly expanding both the capabilities and the complexity of marketing. At the same time, CEOs, CFOs and boards increasingly expect marketing leaders to demonstrate a direct contribution to revenue, profitability and growth.”
Fifty-six percent of the marketing leaders surveyed by ISG identify revenue growth as a key objective for AI initiatives, yet results for profit, cost savings and revenue underperformed expectations by double digits.
“More than one-third of marketers say time saved through AI has not directly translated into savings or value for the enterprise,” Camire said. “The next challenge for marketing leaders is to turn AI-driven efficiency and performance into measurable growth and ROI.”
ISG Marketing Advisory helps enterprises connect marketing investment to revenue impact with expertise in:
Benchmarking marketing investment performance and peer companies;
Operating model and strategy design across workflows, talent and technology to improve productivity and performance;
Marketing ecosystem optimization across martech, agencies and service providers to eliminate duplication and identify clear business impact, and
Governance frameworks that ensure sustained, measurable value.
The new practice also draws on ISG’s expertise as the world’s leading sourcing advisor. ISG influences more than $200 billion in technology spend annually, spanning IT, finance and accounting, human resources, supply chain, contact centers, marketing and other enterprise functions.
In a recent engagement, a global cosmetics and beauty company achieved 45 percent savings across marketing services as part of a broader ISG-advised enterprise transformation. ISG helped restructure the company’s global provider ecosystem, strengthen commercial terms and accountability and establish a framework to govern and measure performance. The resulting marketing model freed capacity for the client to reinvest in higher-value priorities aligned with the company’s strategic growth objectives.
“Marketing leaders are managing increasingly complex portfolios of technology, agencies, service providers, data and talent, often through outdated ways of working,” Camire said. “Without a modern operating model to orchestrate these resources, greater investment can simply create greater complexity. We are working with marketing leaders to shape the next generation of their organizations and to strengthen the contribution marketing makes to profitable enterprise growth.”
Additional information on ISG Marketing Advisory is available here.
About ISG
ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.
View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-to-announce-third-quarter-2026-financial-results-302901916.html
